Please use this identifier to cite or link to this item:
|Title:||Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa|
|Author:||Guerra Mendoza, Yolanda|
Masoud, Nahya Salim
Mtoro, Ali Takadir
Otieno, Godfrey Allan
Hamel, Mary J.
Kremsner, Peter G.
Aide, Pedro Carlos Paulino
Asante, Kwaku Poku
Berkley, James A.
Agnandji, Selidji Todagbe
|Keywords:||Vacuna de la malària|
|Publisher:||Taylor & Francis|
|Abstract:||A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS,S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study. 8922 children (enrolled at 5-17\xC2\xA0months) and 6537 infants (enrolled at 6-12\xC2\xA0weeks) were 1:1:1-randomized to receive 4 doses of RTS,S/AS01 (R3R) or non-malaria control vaccine (C3C), or 3 RTS,S/AS01 doses plus control (R3C). Aggregate safety data were reviewed by a multi-functional team. Severe malaria with Blantyre Coma Score \xE2\x89\xA42 (cerebral malaria [CM]) and gender-specific mortality were assessed post-hoc. Serious adverse event (SAE) and fatal SAE incidences throughout the study were 24.2%-28.4% and 1.5%-2.5%, respectively across groups; 0.0%-0.3% of participants reported vaccination-related SAEs. The incidence of febrile convulsions in children was higher during the first 2-3 days post-vaccination with RTS,S/AS01 than with control vaccine, consistent with the time window of post-vaccination febrile reactions in this study (mostly the day after vaccination). A statistically significant numerical imbalance was observed for meningitis cases in children (R3R: 11, R3C: 10, C3C: 1) but not in infants. CM cases were more frequent in RTS,S/AS01-vaccinated children (R3R: 19, R3C: 24, C3C: 10) but not in infants. All-cause mortality was higher in RTS,S/AS01-vaccinated versus control girls (2.4% vs 1.3%, all ages) in our setting with low overall mortality. The observed meningitis and CM signals are considered likely chance findings, that - given their severity - warrant further evaluation in phase IV studies and WHO-led pilot implementation programs to establish the RTS,S/AS01 benefit-risk profile in real-life settings.|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.1080/21645515.2019.1586040|
|It is part of:||Human Vaccines & Immunotherapeutics, 2019|
|Appears in Collections:||Articles publicats en revistes (ISGlobal)|
Files in This Item:
|GuerraMendozaY_Hum_Vaccin_Immunother_2019.pdf||2.91 MB||Adobe PDF||View/Open|
This item is licensed under a Creative Commons License